- ASX
Proteomics Intl Labs Ltd
Healthcare AU PIQ
0.445AUD
-(-%)
Last update at 2025-04-16T00:37:00Z
Day Range
52 Week Range
Fundamentals
- Previous Close 0.45
- Market Cap60.26M
- Volume38719
- P/E Ratio-
- Dividend Yield-%
- EBITDA-6.73828M
- Revenue TTM3.50M
- Revenue Per Share TTM0.03
- Gross Profit TTM 1.46M
- Diluted EPS TTM-0.06
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Analyst Recommendations
Financials
Income Statement
Balancesheet
Change in Cash
Total Operating Cash
Dividends Paid
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -6.23431M | -4.97296M | -2.85966M | -1.74377M | -2.08027M |
| Minority interest | - | - | - | - | - |
| Net income | -6.23431M | -4.97296M | -2.85966M | -1.74377M | -2.10733M |
| Selling general administrative | 5.11M | 4.36M | 2.87M | 2.24M | 2.16M |
| Selling and marketing expenses | - | 0.12M | 0.06M | 0.08M | 0.23M |
| Gross profit | -1.61511M | -0.56862M | 0.50M | 0.58M | 1.47M |
| Reconciled depreciation | 0.53M | 0.42M | 0.37M | 0.36M | 0.19M |
| Ebit | -8.82815M | -4.97251M | -2.85956M | -1.73486M | -2.05322M |
| Ebitda | -8.29862M | -4.55565M | -2.48704M | -1.37116M | -1.86492M |
| Depreciation and amortization | 0.53M | 0.42M | 0.37M | 0.36M | 0.19M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -6.36560M | -4.97728M | -3.08268M | -1.99821M | -2.05322M |
| Other operating expenses | 4.86M | 4.29M | 3.98M | 2.80M | 4.54M |
| Interest expense | - | 0.00045M | 0.00010M | 0.00891M | 0.03M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.14M | 0.00544M | 0.01M | 0.02M | 0.28M |
| Net interest income | 0.14M | 0.00275M | 0.00805M | 0.01M | 0.02M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.14836M | 1.94M | 1.64M | 1.58M | 0.03M |
| Total revenue | 0.73M | 1.49M | 1.31M | 1.42M | 1.47M |
| Total operating expenses | 9.55M | 8.41M | 5.82M | 4.74M | 4.54M |
| Cost of revenue | 2.35M | 2.06M | 0.81M | 0.84M | 0.81M |
| Total other income expense net | 2.45M | 1.94M | 1.64M | 1.57M | -0.02706M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -6.23431M | -4.97296M | -2.85966M | -1.74377M | -2.08027M |
| Net income applicable to common shares | -6.17657M | -4.97296M | -2.85966M | -1.74377M | -2.08027M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 10.88M | 10.08M | 5.40M | 8.60M | 5.55M |
| Intangible assets | 0.00101M | 0.00101M | 0.00101M | 0.00101M | 0.00101M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.12M | 1.97M | 1.73M | 1.30M | 1.33M |
| Total liab | 1.63M | 1.75M | 2.00M | 0.99M | 1.12M |
| Total stockholder equity | 9.41M | 8.38M | 3.39M | 7.61M | 4.44M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.50M | 0.55M | 1.18M | 0.30M | 0.44M |
| Common stock | 36.81M | 30.18M | 19.34M | 19.10M | 13.39M |
| Capital stock | 36.81M | 30.18M | 19.34M | 19.10M | 13.39M |
| Retained earnings | -29.67104M | -23.62758M | -17.63007M | -12.65711M | -10.00774M |
| Other liab | - | - | 0.30M | 0.21M | 0.43M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.06M | 0.06M | 0.00000M | 0.00000M |
| Cash | 6.64M | 6.03M | 2.11M | 5.60M | 2.37M |
| Cash and equivalents | - | 5.79M | 1.00M | 5.05M | 0.05M |
| Total current liabilities | 0.90M | 1.10M | 1.70M | 0.78M | 0.62M |
| Current deferred revenue | 0.25M | 0.37M | 0.36M | 0.27M | -0.06380M |
| Net debt | -6.32385M | -5.96323M | -2.11151M | -5.53579M | -2.23218M |
| Short term debt | 0.10M | 0.03M | -0.35598M | 0.07M | 0.06M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.32M | 0.06M | 0.06M | 0.07M | 0.13M |
| Other stockholder equity | - | -6.55268M | -1.71084M | -6.43812M | -3.38380M |
| Property plant equipment | - | 1.69M | 0.97M | 1.26M | 1.44M |
| Total current assets | 9.16M | 8.33M | 4.36M | 7.34M | 4.12M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | 3.39M | 7.61M | 4.44M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.41M | 0.21M | 0.44M | 0.30M | 0.36M |
| Long term debt | - | - | - | - | - |
| Inventory | - | 0.12M | 0.08M | 0.13M | 0.06M |
| Accounts payable | 0.06M | 0.15M | 0.52M | 0.14M | 0.18M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 2.27M | 1.83M | 1.68M | 1.17M | 1.05M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 13.39M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -0.00000M | 0.06M | 0.06M | -1.26180M | -1.43711M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.71M | 1.75M | 1.03M | 1.26M | 1.44M |
| Capital lease obligations | 0.32M | 0.06M | - | 0.07M | 0.13M |
| Long term debt total | - | 0.03M | 0.00000M | 0.00000M | 0.07M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -1.16513M | -0.12946M | -0.19100M | -1.58613M | 0.93M |
| Change to liabilities | 0.00000M | 1.01M | -0.14885M | 0.61M | -0.08707M |
| Total cashflows from investing activities | -1.16513M | -0.12946M | -0.19100M | -1.58613M | 0.89M |
| Net borrowings | - | -0.06905M | -0.06380M | -0.16492M | -0.14750M |
| Total cash from financing activities | 10.77M | 0.18M | 5.64M | 2.82M | -0.02875M |
| Change to operating activities | - | -0.36195M | 0.04M | 0.04M | 0.87M |
| Net income | -6.17657M | -4.97296M | -2.85966M | -1.74377M | -2.08027M |
| Change in cash | 3.92M | -3.49332M | 3.24M | 0.85M | -0.80535M |
| Begin period cash flow | 2.11M | 5.60M | 2.37M | 1.51M | 2.32M |
| End period cash flow | 6.03M | 2.11M | 5.60M | 2.37M | 1.51M |
| Total cash from operating activities | -5.69291M | -3.53996M | -2.20907M | -0.38451M | -1.66701M |
| Issuance of capital stock | 10.84M | 0.25M | 5.70M | 3.05M | 0.12M |
| Depreciation | 0.53M | 0.42M | 0.37M | 0.36M | 0.19M |
| Other cashflows from investing activities | 0.05M | 0.00000M | 0.01M | -0.12782M | -0.12782M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 0.29M | -0.13908M | 0.06M | 0.14M | 0.10M |
| Sale purchase of stock | 10.84M | 0.25M | 5.70M | 3.05M | 0.12M |
| Other cashflows from financing activities | -0.06551M | -0.06905M | -0.06380M | -0.06880M | 0.89M |
| Change to netincome | 0.32M | 0.51M | 0.32M | 0.21M | -0.65696M |
| Capital expenditures | 1.22M | 0.13M | 0.21M | 1.59M | 0.04M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.29M | -0.13908M | 0.06M | 0.14M | 0.13M |
| Stock based compensation | 0.32M | 0.51M | 0.33M | 0.15M | - |
| Other non cash items | -0.04587M | 1.02M | 0.28M | 1.00M | 1.89M |
| Free cash flow | -6.91082M | -3.66942M | -2.41424M | -1.97064M | -0.03799M |
Peer Comparison
Sector: Healthcare Industry: Biotechnology
| Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PIQ Proteomics Intl Labs Ltd |
- -% | 0.45 | - | - | 17.24 | 11.04 | 61.08 | -19.4827 |
| CSL CSL Ltd |
-2.17 0.90% | 239.72 | 25.69 | 33.33 | 7.48 | 3.76 | 5.46 | 16.93 |
| TLX Telix Pharmaceuticals Ltd |
-0.24 0.93% | 25.63 | 189.86 | 59.17 | 11.36 | 15.66 | 11.20 | 94.74 |
| MSB Mesoblast Ltd |
0.03 1.67% | 1.65 | - | 454.55 | 348.74 | 2.84 | 246.99 | -9.8623 |
| NEU Neuren Pharmaceuticals Ltd |
0.17 1.67% | 10.34 | 8.56 | 56.18 | 5.51 | 3.37 | 4.70 | 5.71 |
Reports Covered
Profile
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for diabetic kidney disease in type 1 diabetes; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy; and Giardia, a causing gastroenteritis. The company also offers analytical services, such as pharmacokinetic testing, biomarker discovery, protein analysis, project consultation, and specialist contract research. Proteomics International Laboratories Ltd was founded in 2001 and is headquartered in Perth, Australia.
Proteomics Intl Labs Ltd
QEII Medical Centre, Perth, WA, Australia, 6009
- 61 8 9389 1992
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Richard John Lipscombe M.A., MA (Oxford), Ph.D., Ph.D., (London) | Co-Founder, MD & Director | NA |
| Ms. Jacqueline Gray | Chief Financial Officer | NA |
| Mr. Vikesh Malik | Chief Commercialisation Officer | NA |
| Mr. John Chuck Morrison | Head of Bus. Devel. | NA |
| Dr. Scott Bringans | Head of Research | NA |
| Dr. Pearl Tan | Head of Logistics | NA |
| Dr. Kirsten Peters | Head of Clinical Studies | NA |
| Ms. Karen Teresa Logan B.Com., FCIS, BCom, DipAppCorpGov, FFin, ACIS, AGI | Company Sec. | NA |
| Mr. John Chuck Morrison | Head of Business Development | NA |
| Ms. Karen Teresa Logan ACIS, B.Com., BCom, DipAppCorpGov, F Fin, FCIS, FC | Company Secretary | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
